Get research updatesSchizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
This study evaluated the safety of ASP4345 for people with schizophrenia.
This study has finished and is no longer accepting participants.
In GlendaleA Phase 3, Multicenter, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including HefeiThis study evaluated the safety and effectiveness of ASP4345 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including CerritosThis study evaluated the safety of ASP6981 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including GlendaleClinical Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
This study has finished and is no longer accepting participants.
Multiple locations, including ButareA Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockA Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveThis study evaluated the safety of Iloperidone for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of KYN-5356 as Adjunctive Treatment in Adults With Cognitive Impairment Associated With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockA Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult Subjects With Schizophrenia
This study has finished and is no longer accepting participants.
In GaithersburgResearchers compared RL-007 (Inidascamine) and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Culver CityResearchers are studying Emraclidine 30 mg, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.
This study ended early.
Multiple locations, including PhoenixWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.